Published • loading... • Updated
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
The 5-patient cohort showed a 100% confirmed response rate among those with target lesions and no grade 3 or higher cytokine release syndrome, researchers said.
- On Saturday, May 30, 2026, CARsgen Therapeutics Holdings Limited presented long-term analysis results of satricabtagene autoleucel at the 2026 ASCO Annual Meeting for sequential therapy in advanced gastric/gastroesophageal junction adenocarcinoma .
- Satri-Cel is an autologous CAR T-cell product candidate targeting the protein Claudin18.2, designed to address unmet clinical needs in patients with advanced G/GEJA following first-line chemotherapy.
- Among five patients, the confirmed objective response rate was 100% in four patients with target lesions, and median progression-free survival since first-line therapy was 20.9 months.
- The analysis showed a manageable safety profile with no grade 3 or higher cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome , and two patients underwent surgical resection after satri-cel therapy.
- CARsgen is actively expanding satri-cel applications, including ongoing Phase I clinical trials for pancreatic cancer adjuvant therapy, following Priority Review and Breakthrough Therapy Designation granted by the CDE in 2025.
Insights by Ground AI
36 Articles
36 Articles
LoudounTimes.com+35 Reposted by 35 other sources
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against…
Coverage Details
Total News Sources36
Leaning Left5Leaning Right5Center11Last UpdatedBias Distribution52% Center
Bias Distribution
- 52% of the sources are Center
52% Center
L 24%
C 52%
R 24%
Factuality
To view factuality data please Upgrade to Premium
